Cape Cod restaurant news: Bar opens at Provincetown's Pilgrim Monument, bakery changes
In news you've been waiting for, Nantucket's famous Bartlett Farm opened a second farm in West Barnstable on Memorial Day weekend.
Last week, Days on the Pier opened on MacMillan Wharf in Provincetown; folks are celebrating the 16th annual Wellfleet Restaurant Week through June 3; and we took a look at restaurants that have opened in the past year.In our Dinner and a Show feature, we spoke to Cape Rep Theatre director Julie Allen Hamilton about 'Every Brilliant Thing' and recommended two restaurants near the Brewster theater.
Here's the most recent news:
Eat Cake 4 Breakfast has been purchased by the Nelson siblings. You may know the Nelsons ― Tori, 31, Tara, 30, and Todd F. Nelson Jr., or TJ, 25 ― from the summer of 2023 when they ran the Cousins Maine Lobster truck parked on Route 6A in Yarmouth Port or sometimes at Mashpee Commons.
The bakery's founder, Le Cordon Bleu alum Danielle Nettleton, brought her French training to Eat Cake 4 Breakfast when she opened in 2015 and earned a reputation for rich, layered croissants (chocolate and pistachio is a favorite), scones, cookies and Brewster Buns ― a cinnamon roll made with croissant dough.
For the past few weeks, Nettleton has been giving the Nelsons a crash course in baking. Although the new owners are, through their website eatcake4breakfast.com, looking to hire a full-time pastry chef, they also want to know how everything is made.
The siblings said they are aiming to re-open in early to mid-June, with all of Nettleton's specialties.
'We know how many people love this place and we want to keep it just the same for them,' TJ Nelson said.
But the new owners are also eventually looking to add some lunch sandwiches, fancy coffee drinks and gelato ― as well as extended hours. When they get to the point of adding some of their own baked goods, the siblings said, the first will be a chocolate snack cake with cream filling that they grew up making with their great aunt, Louise Romano, who died a few weeks ago.
Nettleton said Eat Cake 4 Breakfast sold for $1.35M with the property. She said she is moving to Litchfield County, Connecticut, to raise her daughter with the help of family.
Eat Cake 4 Breakfast, 26 Wampum Drive, Brewster, 508-896-4444, eatcake4breakfast.com
The new Shallop Bar is open to serve craft cocktails or mocktails to anyone who has paid admission to Pilgrim Monument & Provincetown Museum or is a member of the nonprofit. Individual membership is $60 or $75 for two.
'Whether you're here for the view, the history or the vibe, this is your perfect pit stop,' organizers wrote. The Shallop Bar will be 'captained' by the monument's new food and beverage director Greg Whittle, according to the post.
Pilgrim Monument & Provincetown Museum, 1 High Pole Hill Road, Provincetown, 508-487-1310, pilgrimmonument.org/.
Duffy Health Center's Colors of Hope Online Auction, live through 8 p.m. June 6, has gift cards to some favorite local spots, including Alberto's, Scargo Café, Stars Restaurant at Chatham Bars Inn, Mike's Roast Beef, The Knack (Hyannis & Orleans), Stage Stop Candy, Snowy Owl Coffee, Veteran's Lunch Box Food Truck, and even a membership to the Captain's Table at Hyannis Yacht Club.
Bid at e.givesmart.com/events/lmb/i/. All proceeds support Duffy Health Center's work with individuals experiencing homelessness on Cape Cod.
Seventh-generation farmers John and Sarah Bartlett have opened a mainland location of the Nantucket farm that's been in their family for more than 200 years. The new farm is located at 2199 Main St. in West Barnstable on the land that was formerly Harvest Moon Farm. The farm will be open daily, selling seasonal produce, flowers and locally made goods, according to its website, bartlettsfarmwestbarnstable.com/.
"Rain, wind, and a full-blown nor'easter couldn't stop us from kicking off our first season in West Barnstable. We'll be here every day from 10 a.m.– 6 p.m., ready with farm-fresh goods, local favorites, and everything you need to brighten up this soggy start to the weekend," Bartlett Farm staffers wrote on the farm's Instagram.
Gwenn Friss is the editor of CapeWeek and covers entertainment, restaurants and the arts. Contact her at gfriss@capecodonline.com. Join the Cape Cod Times free Facebook group, Good Stuff at Cape Cod Restaurants, to share tips and participate in food polls.
Thanks to our subscribers, who help make this coverage possible. If you are not a subscriber, please consider supporting quality local journalism with a Cape Cod Times subscription. Here are our subscription plans.
This article originally appeared on Cape Cod Times: Cape Cod restaurants: Brewster bakery to reopen; Pilgrim Monument bar
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
4 hours ago
- New York Post
Trump's tariff plan seems to be working — proving all the naysayers wrong
For all the 'sky-is-falling' cries over President Donald Trump's tariffs, it looks like his strategy may be working — just as his Aug. 1 deadline nears. In the past week, the Trump folks struck deals with Japan, Indonesia and the Philippines — and may be on the verge of a deal with Europe: On Friday, the prez cited a 50-50 chance of reaching an agreement with the European Union. These developments — on top of previous deals with Vietnam, the United Kingdom and a framework on rare-earth exports and tech restrictions with China — go a long way toward standing up Trump's vision for the international economy, with better terms for America. And at least so far, no catastrophic fallout. Heck, the nation looks poised to benefit enormously on several fronts. Trump's deals in Asia, for starters, reopen US access to cheap markets, sidestepping China, our greatest economic and military rival. Indonesia and the Philippines will pay 19% tariffs on their exports to the United States and levy 0% tariffs on more than 99% of US goods. Japan will see 15% tariffs and invest more than half a trillion dollars into the US economy. Washington will also slap fewer restrictions on Indonesian, Filipino and Japanese goods, everything from cars and clothes to electronics and rubber. And now EU officials are signaling their support for a deal that would mirror the one Trump made with Japan — reciprocal tariffs of 15%. Notably, the EU includes 27 countries in a shared common market, representing the largest singular trading bloc for the United States. The EU deal would clearly benefit US consumers looking to buy, say, French wines or German cars, and also US producers seeking wider access to the European markets. Keep up with today's most important news Stay up on the very latest with Evening Update. Thanks for signing up! Enter your email address Please provide a valid email address. By clicking above you agree to the Terms of Use and Privacy Policy. Never miss a story. Check out more newsletters Meanwhile, the resolution of trade issues with so many countries will calm markets and bring confidence and stability to the business community. As for the predicted inflation, it's nowhere to be seen: June's consumer price index came in at a reasonable 2.7%. Recall it hit 9% under Joe Biden. That's partially because corporations, unsure of whether high tariffs will remain permanent and nervous about hiking prices, have absorbed most of the tariffs' costs, at least for now. More good news: The tariffs brought in $64 billion in revenue for the government in just the first three months since Trump's April 2 'Liberation Day' announcement. He's suggested issuing 'rebates' based on that haul, but far better to use the new revenue to pay down the runaway national debt. Yes, there's plenty more to do: Team Trump needs to finalize agreements with Canada, India and Mexico, along with the EU, and numerous smaller countries, before the president's across-the-board reciprocal tariffs hit Aug. 1. So considerable uncertainty remains. But clearly the signs are good, at least so far — despite all the doomy predictions.
Yahoo
5 hours ago
- Yahoo
Pharma braces for critical French drug pricing reforms pending CEPS's report
Growing budgetary pressure is a central theme in France as the country prepares for the publication of the government's 2026 Social Security Finance Bill (PLFSS). French Prime Minister François Bayrou has requested the Economic Committee for Health Products (CEPS) to create a report, which will be published by the end of July 2025 and released in Q3 2025, outlining its drug pricing policy recommendations. These policy recommendations are likely to be defined by what Bayrou describes as 'changing geopolitical context' and 'investment dynamics' for the EU pharma sector. The environment has therefore triggered an opportunity to re-evaluate current price setting and regulation policies, with the potential for greater flexibility and higher prices due to changing business conditions. This principle is already starting to be put in place. From March 2025, the CEPS has been required to consider the manufacturing location of production sites when setting prices, known as the 'industrial criterion'. While this policy existed previously, it is now mandated, giving preferential pricing for domestically manufactured medicines. A price premium for local manufacturing will likely improve the generic sector, making it more financially viable. Historically, financial viability has been a definitive struggle for generic and biosimilar manufacturers in France. Based on a sample of off-patent, generic, and biosimilar prices, these medicines are typically priced between 38% to 68% lower in France, on average, when compared to the other top European markets. Using the available current prices from GlobalData's Price Intelligence (POLI) & HTA service, the figure below compares the average price per milligram per unit of pack (one tablet, for example) difference between off-patent, generic, and biosimilar medicines that are available in France and the other four major European markets. The sample from each drug type was generated by including products that have their strength measured in milligrams and are available in all five markets. Figure 1: Average price per strength unit (euros/unit/mg) comparison of prices in France to the other EU5 market Furthermore, the Generic Same Drug Association (GEMME) in France has pushed for biosimilars to be excluded from the 'safeguard clause' pricing policy. This measure limits public health spending on medicines by requiring pharmaceutical companies to contribute to health spending once the reimbursed expense exceeds a set threshold. There may be further positive news for generics and biosimilars as the government also considers lowering the discount ceiling for generics from 40% down to 20%–25% while setting a low ceiling for biosimilars. While the upcoming report from CEPS will likely have benefits for the generic/biosimilar sector, it is unclear what potential benefits will be brought to the innovative pharmaceutical sector. There are appeals to change the 'safeguard clause' and lower the cap, and there are possible modifications, but it is unlikely to be entirely overhauled. It is more likely that other cost-saving measures will be considered. For example, medicines with low clinical value ratings (Service Médical Rendu, SMR) could be delisted. Products that are reimbursed at the lowest tier (15%) would therefore no longer be reimbursed. Such measures would likely target non-essential and lifestyle medicines that receive this low SMR rating in their cost-effectiveness assessments. GlobalData's Price Intelligence (POLI) & HTA service shows that 77 molecules are currently 15% reimbursed and could therefore face a delisting challenge. These products see an average first price cut similar to that of products with a higher clinical rating. The average first price cut across different reimbursement tiers ranges between 6% and 7% for the different clinical ratings. Therefore, products with a low clinical rating see a similar impact on price after launch compared to those with a higher rating, despite being more likely to have competition with alternative treatments on the market. Figure 2: Average first price cut (%) of products based on reimbursement level granted Additionally, France's National Health Insurance Agency (Caisse Nationale d'Assurance Maladie, CNAM) has set out proposals to save on pharmaceutical spending. In its annual report, CNAM suggested that medicines with an improvement in actual benefit (Amélioration du Service Médical Rendu, ASMR) that are rated 'absent/no improvement' (ASMR V) or 'minor' (ASMR IV) should be subject to a discount compared to the net price of the cheapest available comparator. The figure below shows the proportion of brands in France by ASMR ratings granted. More than 70% of brands, accounting for the majority of the medicines reimbursed in France, have been granted these ratings of ASMR IV or V and would therefore be impacted. Figure 3: Distribution of medicines in France by ASMR rating Throughout 2025, CEPS has been coordinating many policy initiatives that will determine and influence the government's approach to pharmaceutical spending in 2026. As such, the French Government has requested that the CEPS publish a report later in July 2025 to outline its policy recommendations. While this appears to be a quick turnaround for CEPS, the ongoing initial proposals have given a sneak peek into what this report may feature. The generic and biosimilar sectors are likely to benefit from upcoming reforms. Potential amendments could include changes to the limit discount ceiling and possible exclusion from the 'safeguard policy'. It is unclear what this report may consider for the innovative sector; however, certain medicines could be delisted based on reimbursement levels, and further discounts could be granted on net prices for products with ASMR IV and V ratings. This report will encompass the progress made for recent and upcoming policy actions, while also giving insight into significant spending constraints for innovative medicines expected for 2026. This article is produced as part of GlobalData's Price Intelligence (POLI) service, the world's leading resource for global pharmaceutical pricing, HTA and market access intelligence integrated with the broader epidemiology, disease, clinical trials and manufacturing expertise of GlobalData's Pharmaceutical Intelligence Center. Our unparalleled team of in-house experts monitors P&R policy developments, outcomes and data analytics around the world every day to give our clients the edge by providing critical early warning signals and insights. For a demo or further information, please contact us here. "Pharma braces for critical French drug pricing reforms pending CEPS's report" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
New York Post
6 hours ago
- New York Post
Louis Vuitton owner LVMH in talks to sell Marc Jacobs in deal that could fetch $1B: report
French luxury goods group LVMH is in discussions to sell fashion label Marc Jacobs in a deal that could fetch around $1 billion, the Wall Street Journal reported Friday, citing people familiar with the matter. In 2024, Bloomberg reported that LVMH was exploring strategic options for the label with advisers after receiving interest from potential buyers, though the company denied the claim at the time. The Bernard Arnault-led company has been discussing deals with multiple parties, including Reebok-owner Authentic Brands, Brookstone-owner Bluestar Alliance and Vera Wang parent WHP Global, the newspaper said on Friday. 3 French luxury giant LVMH is in discussions to sell fashion label Marc Jacobs in a deal that could fetch around $1 billion, the Wall Street Journal reported. Getty Images for Marc Jacobs Reuters was unable to immediately verify the report. LVMH, Marc Jacobs and the potential buyers did not immediately respond to Reuters' requests for comments. The Journal said that a deal could be finalized soon, provided talks don't fall apart. Dealmaking in the luxury retail sector has drawn attention in Europe. Earlier this year, Prada acquired Versace from Capri Holdings, combining two iconic Italian fashion brands in a $1.4 billion deal. LVMH's second-quarter sales, which include products such as Louis Vuitton handbags, Dior dresses and Moet & Chandon champagne, came in slightly below market expectations. 3 The Bernard Arnault-led LVMH has been discussing deals with multiple parties. AP 3 Dealmaking in the luxury retail sector has drawn attention in Europe. Earlier this year, Prada acquired Versace from Capri Holdings, combining two iconic Italian fashion brands in a $1.4 billion deal. Marc Jacobs handbags, above. Getty Images for Marc Jacobs French luxury brands have been navigating prolonged market challenges, including a downturn and the potential impact of US import tariffs.
